Payment overview · 2025
General Payments
$65.58
3 reported records · 2 companies
Healthcare provider profile · identity verified
Walter Rivera, M.D
Allopathic & Osteopathic Physicians|General Practice · ARECIBO, PR · NPI 1609886969
Verified facts
What the public records show
CMS Open Payments records show Walter Rivera, M.D received $65.58 in general payments during 2025 across 3 reported records.
AstraZeneca Pharmaceuticals LP accounted for 68.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45.07 | 68.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.51 | 31.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $65.58 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 127 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
127 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
49 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1202 | 146 |
| Famotidine | Famotidine | 882 | 123 |
| Atorvastatin Calcium | Atorvastatin Calcium | 763 | 189 |
| Synthroid | Levothyroxine Sodium | 756 | 83 |
| Losartan Potassium | Losartan Potassium | 391 | 91 |
| Lisinopril | Lisinopril | 353 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 336 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 332 | 59 |
| Alendronate Sodium | Alendronate Sodium | 317 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 299 | 51 |
| Simvastatin | Simvastatin | 272 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 263 | 32 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 262 | 43 |
| Metformin Hcl | Metformin Hcl | 259 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 255 | 37 |
| Omeprazole | Omeprazole | 250 | 52 |
| Glipizide | Glipizide | 229 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 226 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 211 | 41 |
| Montelukast Sodium | Montelukast Sodium | 211 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 204 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 200 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 197 | 35 |
| Furosemide | Furosemide | 176 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 167 | 49 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 154 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 151 | 47 |
| Carvedilol | Carvedilol | 139 | 23 |
| Betamethasone Valerate | Betamethasone Valerate | 136 | 34 |
| Baclofen | Baclofen | 129 | 41 |
| Farxiga | Dapagliflozin Propanediol | 127 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 22 |
| Finasteride | Finasteride | 121 | 15 |
| Allopurinol | Allopurinol | 120 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 120 | 20 |
| Temazepam | Temazepam | 112 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 18 |
| Spironolactone | Spironolactone | 92 | 15 |
| Cilostazol | Cilostazol | 90 | 11 |
| Sucralfate | Sucralfate | 87 | 17 |
| Latanoprost | Latanoprost | 85 | 11 |
| Atenolol | Atenolol | 81 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 81 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | suppressed |
| Ezetimibe | Ezetimibe | 77 | 15 |
| Donepezil Hcl | Donepezil Hcl | 69 | suppressed |
| Lansoprazole | Lansoprazole | 66 | suppressed |
| Colchicine | Colchicine | 65 | suppressed |
| Humalog | Insulin Lispro | 63 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 63 | suppressed |
| Eliquis | Apixaban | 59 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Jardiance | Empagliflozin | 49 | 14 |
| Pentoxifylline | Pentoxifylline | 47 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 15 |
| Clotrimazole | Clotrimazole | 42 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Ketoconazole | Ketoconazole | 40 | 18 |
| Nitroglycerin | Nitroglycerin | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | 19 |
| Prednisone | Prednisone | 36 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 36 | 18 |
| Diltiazem Hcl | Diltiazem Hcl | 34 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 34 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 33 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Lumigan | Bimatoprost | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Nabumetone | Nabumetone | 31 | 15 |
| Azithromycin | Azithromycin | 30 | 29 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Naproxen | Naproxen | 27 | 12 |
| Cimetidine | Cimetidine | 26 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 18 |
| Verapamil Hcl | Verapamil Hcl | 26 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 20 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Etodolac | Etodolac | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65.58 · 3 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, JARDIANCE | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error